<DOC>
	<DOCNO>NCT00434304</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetic profile , safety efficacy Parkinson 's Disease patient .</brief_summary>
	<brief_title>Clinical Evaluation Ropinirole PR/XR Tablets Monotherapy Parkinson 's Disease ( PD )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Patients diagnose PD severity Modified Hoehn &amp; Yahr staging Stage I III . Age : 20 year old ( time give informed consent ) Gender : male female Both inpatient outpatient status Informed consent : Patients able give inform write consent person ( i.e . patient capable give informed write consent one 's ) Limited prior exposure low moderate dos Ldopa ( 3 month total ) dopamine agonist ( 6 month total ) provide treatment discontinue minimum 4 week prior screen . Patients present serious physical sign symptom PD ( e.g . cardiac/hepatic/renal disorder haematopoietic disorder ) . The seriousness refers Grade 3 accord `` Classification Severity Adverse Experiences ( Pharmaceutical affair bureau/Safety division ( PAB/SD ) Notification No . 80 , date 29 June 1992 ) . Patients symptomatic postural hypotension . ( e.g . dizziness syncope ) . Patients serious psychiatric symptom ( e.g . confusion , hallucination , delusion , abnormal behaviour , alcohol drug dependence ) past six month ( 26 week ) ( include symptom cause antiParkinson drug ) . Patients treat follow drug Week 4 , whose treatment regimen drug change Week 4 Week 0 . Anticholinergic agent : trihexyphenidyl hydrochloride ( e.g . Artane® ) , piroheptine hydrochloride ( Trimol® ) , mazaticol hydrochloride ( Pentona® ) , metixene hydrochloride ( Cholinfall® ) , biperiden hydrochloride ( Akineton® ) , profenamine ( Parkin® ) amantadine hydrochloride ( e.g . Symmetrel® ) droxidopa ( Dops® ) citicoline ( e.g . Nicholin® ) selegiline hydrochloride ( FP® ) zonisamide estrogen : estriol ( e.g.Estriel® ) CYP1A2 inhibitor : Ciprofloxacin HCl ( e.g . Ciproxan® , enoxacin fluvoxamine ) Patients severe dementia score 3 4 UPDRS Part I ( Mentation , behaviour , mood ) Female patient pregnant lactating , may pregnant , plan pregnancy study within 30 day last dose study drug . Patients current history complication carcinoma malignant tumour . Patients history drug allergy ropinirole hydrochloride ( HCl ) . Patients receive surgical treatment PD past ( e.g . pallidectomy , deep brain stimulation ) . Patients treat investigational drug within 12weeks prior treatment phase . Others investigator ( sub investigator ) considers ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>PD</keyword>
</DOC>